Summary.-Many previous reports testify to the effectiveness of bleomycin as a drug for the clinical treatment of squamous carcinomata, and some radiotherapists have considered the possibility that an improved therapeutic ratio might be obtained by combined treatment with bleomycin and radiation. This consideration has been stimulated by recent reports of the effects of combined treatment with bleomycin using mammalian cells in vitro. Experiments are described here in which a murine squamous carcinoma has been used to obtain a survival curve for cells of tumours treated in vivo with single doses of bleomycin alone or in combination with radiation given before or after the drug. The survival curve for drug alone was a multicomponent curve with Do values of 0.1, 0-75 and2-7mg/kg. However,theresultsof the experiments with combined treatment showed no evidence of potentiation.
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BLEOMYCIN is an anti-tumour drug discovered by Umezawa et al. (1966a, b) . Investigations have been made of its actions on mammalian cells (Kunimoto, Hori and Umezawa, 1967; Terasima, Yasukawa and Umezawa, 1970; Terasima and Umezawa, 1970) . The drug has been used clinically and has shown strong antitumour activities against human tumours, being specifically remarkably effective against squamous carcinoma (Ichikawa, 1969; Miyake and Inuyama, 1971; Blum, Carter and Agre, 1973) . However, there are no experimental data demonstrating its effect on squamous carcinoma. Recently, Matsuzawa et al. (1972) suggested that bleomycin had a potentiating effect when used in combination with radiation.
The purpose of the present work was to determine the dose survival relationship with a murine epithelioma, whose response to bleomycin has not yet been studied, and to ascertain whether or not bleomycin interacts with radiation in our tumour system as it appears to do in vitro.
MATERIALS AND METHODS
Mlice.-Male or female mice of strain WHT/Ht were used as tumour hosts in the TD50 experiments.
Tumour.-This was a transplantable keratinizing squamous carcinoma which arose spontaneously in a WHT/Ht mouse and has since been maintained by serial passage subcutaneously. A full description of the tumour has been reported by Hewitt, Chan and Blake (1967) and Hewitt and Sakamoto (1971) .
Treatment with bleomycin.-The stock solution of bleomycin was prepared at a concentration of 5 0 mg/ml in saline from powder as is used clinically. For use, the stock solution was diluted with saline to give a range of concentration of the drug from 0 03 mg/ml to 2-0 mg/ml, in order to keep the volume of 0 3 ml as a constant volume, to be injected intraperitoneally with changes in drug dose. * Present address: Department of Radiation Biophysics, Faculty of Medicine, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113, Japan.
Irradiation. X-rays were geneiated by a therapy machine operated at 180 kVp and 20 mA and were filtered through 0 7 mm Cu and 0-5 mm A]. The exposure rate, measured with a Victoreen condenser chamber (Model 570) without any additional absorber, using the calibration factor supplied by the Electro Technical Laboratories, Tokyo, was 78 rad/min; the FSD w%as 35 cm. Single unanaesthetized tumour bearing mite were exposed to whole body irradiation while confined in a perforated Perspex cylinder, immediately before or at 1 h after bleomycin treatment.
Survival of tumour cells. Tumour bearing mice were prepared by the subcutaneous injection of 80,000 tumour cells into each axilla 10-11 days before treatment; the tumour at this stage weighed 1-5-2-0 g. The mice were treated intraperitoneally with a range of doses of bleomycin 1 h before killing. Single-cell suspensions of tumours cells were prepared from the tumours by a method described previously (Hewitt, 1966) . Transplantation assays of counted suspensions were performed by the technique described by Hewitt et al. (1967) . The TD50 (1949) . A series of assays of cells from untreated tumours yielded a mean TD50 of 9-6 cells. The surviving fraction of cells from treated tumours was therefore obtained from the expression 9.6/TD50 for treated cells.
RESULTS

Survival of tumour cells treated by bleomycin
The single-dose survival curves of the squamous carcinoma cells exposed to bleomycin are shown in Fig. 1 and 2 . The curve in Fig. 1 has 2 Fig. 2 corresponds to the second component in Fig. 1 .) In Fig. 2 the second component shifts to the third component at a dose level of 2-5 mg/kg, the Do of the third component being 2-7 mg/kg. The explanation for the trimodal response to the drug, indicated by the shape of the survival curve, is not clear but will be considered further in the Discussion.
Survival of tumour cells treated by combined bleomycin and radiation
Figures 3 and 4 show the survival of squamous carcinoma cells given combined treatment with bleomycin and x-rays. In Fig. 3 the open circles indicate the survival of tumour cells exposed to graded doses of x-rays 1 h after treatment with 03 mg/kg of bleomycin; the closed circles show the survival of tumour cells treated with 03 mg/kg of bleomycin for 1 h immediately after exposure to graded doses of x-rays. Figure 4 shows the results of similar experiments to those in Fig. 3 , except that 1 0 mg/kg of bleomycin was given instead of 0 3 mg/kg (as in the experiments shown in Fig. 3 ). In Fig. 3 and 4 the solid lines are superimposed from previously published data (Sakamoto and Sakka, 1973a) Solid line is superimposed from previously published data (Sakamoto and Sakka, 1973a) . Iinterrupted line shows the expected tumour cell survivals if bleomycin has only an additive cell killing effect with x-rays.
DISCUTSSION
The compound survival curve obtained for bleomycin shows some resemblance to that commonly obtained for cells of solid tumours irradiated in vivo (Powers and Tolmach, 1963; Clifton, Briggs and Stone, 1966; Reinhold, 1966) , in which the cell population exposed consists of a mixture of oxygenated and hypoxic cells of widely different radiosensitivities. The bleomycin dose survival curve also resembles the survival curve for epithelioma cells exposed to neocarzinostatin (Sakamoto and Sakka, 1973b) , except for the third component in the survival curve for bleomycin. In the case of the survival curve for bleomycin, its shape is open to several possible interpretations: (1) hypoxic cells may be more resistant to the drug, as they are to irradiation; (2) the cell population may consist of 3 components differing in sensitivity to the drug on account of some feature other than their oxygenation; (3) the more resistant cells niay be those less accessible to the drug because of vascular deficiency; (4) there may be a limiting concentration of drug, above which there is no enhancement of cytolethality, additional drug being wasted ". Matsuzawa et al. (1972) suggest that bleomycin potentiates the effect of x-rays using mouse cancer cells in vitro; Bienkowska, Dawson and Peacock (1973) showed no interaction between bleomycin and x-rays using HeLa cells. In ouir experimental system, bleomycin shows no potentiating effect with x-rays. In the experiment using combined treatment, we administered x-ray doses over 1000 rad, but recently it has become clear that there is no potentiating effect even with a dose of less than 1000 rad.
Bleomycin has been reported to have a remarkable effect on clinical squamous carcinomata; it was also found to be as effective in the present experimental system as neocarzinostatin given in doses 10 times as large (Sakamoto and 
